Predict your next investment

Corporation
HEALTHCARE | Medical Facilities & Services / Specialized Healthcare Services
vantageoncology.com

See what CB Insights has to offer

Total Raised

$117.5M

Investors Count

9

Deal Terms

2

Vantage Oncology Funding, Vantage Oncology Valuation & Vantage Oncology Revenue

8 Fundings

Vantage Oncology's latest funding round was a Acquired for on February 25, 2016.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/25/2016

Acquired

3

2/18/2011

Private Equity

0

7/11/2008

Series E

$99M

0

2/6/2007

Series D

$99M

0

8/9/2006

Series C

$99M

0

Date

2/25/2016

2/18/2011

7/11/2008

2/6/2007

8/9/2006

Round

Acquired

Private Equity

Series E

Series D

Series C

Amount

$99M

$99M

$99M

Investors

Valuation

Revenue

Sources

3

0

0

0

0

Vantage Oncology Deal Terms

2 Deal Terms

Vantage Oncology's deal structure is available for 2 funding rounds, including their Series B from June 21, 2004.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Vantage Oncology Investors

9 Investors

Vantage Oncology has 9 investors. McKesson invested in Vantage Oncology's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

2/25/2016

2/25/2016

1
Acquired

Corporation

Texas

00/00/0000

00/00/0000

Oak Hill Capital Partners

Subscribe to see more

Private Equity

Connecticut

00/00/0000

00/00/0000

Versant Ventures

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

New Enterprise Associates

Subscribe to see more

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Meritech Capital Partners

Subscribe to see more

Venture Capital

California

First funding

2/25/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

2/25/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Oak Hill Capital Partners

Versant Ventures

New Enterprise Associates

Meritech Capital Partners

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Type

Corporation

Private Equity

Venture Capital

Venture Capital

Venture Capital

Location

Texas

Connecticut

California

California

California

Vantage Oncology Acquisitions

2 Acquisitions

Vantage Oncology acquired 2 companies. Their latest acquisition was Radiation Oncology Services of America on August 23, 2013.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/23/2013

$99M

Acquired

1

2/23/2011

Private Equity

Subscribe to see more

$99M

Subscribe to see more

0

Date

8/23/2013

2/23/2011

Investment Stage

Private Equity

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acquired

Subscribe to see more

Sources

1

0

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.